Postoperative radiation therapy for stage IB-IIB carcinoma of the cervix with poor prognostic factors

Takashi Uno, Hisao Ito, Jun Itami, Shigeo Yasuda, Koichi Isobe, Ryusuku Hara, Takashi Sato, Shigeki Minoura, Naoyuki Shigematsu, Atsushi Kubo

Research output: Contribution to journalArticlepeer-review

26 Citations (Scopus)

Abstract

Background: To investigate failure pattern and to evaluate the prognostic impact of lymph node metastasis in patients with cervical cancer treated with post operative adjuvant pelvic irradiation. Materials and Methods: Ninety-eight patients with FIGO IB to IIB cervical cancer were treated with radical hysterectomy, bilateral pelvic lymphadenectomy and postoperative radiation therapy. All the patients had at least one of the following pathologic risk factors for pelvic recurrence; 1) positive margins, 2) positive pelvic lymph nodes other than common iliac node, 3) deep stromal invasion more than 50% or parametrial invasion. Results: The 5-year overall survival (OAS) rate for the entire patient group was 82%. Causes of the first failure were pelvic recurrence in 5 cases and distant metastasis in 15 cases. Fifteen of the 47 patients with positive pelvic lymph nodes developed distant metastasis, whereas distant metastasis was noted in only 1 of 51 patients without lymph node metastasis. The 5-year OAS rates for patients with and without pelvic lymph node metastasis were 76% and 89%, respectively (p = 0.018). Conclusion: Despite receiving postoperative pelvic irradiation, apparently lower survival was observed for node positive patients.

Original languageEnglish
Pages (from-to)2235-2239
Number of pages5
JournalAnticancer research
Volume20
Issue number3 B
Publication statusPublished - 2000

Keywords

  • Carcinoma
  • Pelvic lymph node metastasis
  • Radiation therapy
  • Radical hysterectomy
  • Uterine cervix

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Postoperative radiation therapy for stage IB-IIB carcinoma of the cervix with poor prognostic factors'. Together they form a unique fingerprint.

Cite this